Clinical Development & Regulatory Track
From helping trial recruitment to developing natural history studies – creating patient registries that are meaningful in drug development
- Patients, industry and other stakeholders’ contribution to produce better quality registry data
- What technology developments exist to optimize data collection, analysis and curation?
- What are the characteristics of a high quality registry?
Tiina Urv, Program Director, Office of Rare Disease Research, National Center for Translational Sciences, National Institute of Health